News AI start-up Profluent nabs Lilly as first big pharma partner AI start-up Profluent has signed a major alliance with pharma group Eli Lilly, worth up to $2.25bn, that will focus on gene-editing therapies.
News ADC specialist Solve raises $120m, and other biofinancings Our round-up of biofinancings is led by a $120m round for ADC specialist Solve, with Aspen, Artios, Profluent, and Gate Bioscience also raising funds.
News NICE backs UCB drug as first uncontrolled gMG therapy UCB's Rystiggo can be used by the NHS as a backup treatment for people with the rare autoimmune and neuromuscular disease gMG, says NICE.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.